echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: Barrettini combined with Redsiwe to accelerate the recovery of new coronary pneumonia inpatients

    NEJM: Barrettini combined with Redsiwe to accelerate the recovery of new coronary pneumonia inpatients

    • Last Update: 2020-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Patients with severe 2019 coronavirus disease (Covid-19) develop inflammatory disorders that increase the risk of adverse prognosis.
    researchers recently examined the treatment of patients with neocytic pneumonia by Janus kinase inhibitor Barrettinib.
    the study was a randomized, double-blind, placebo-controlled study that examined the efficacy of Barrettinib and Redsiway in hospital patients with neocytosis.
    patients were randomly treated with barrettinib (no more than 14 days) or a placebo on the basis of Redsiway (no more than 10 days of treatment).
    end of the study was recovery time, and the secondary endpoint was the clinical state of the patient after 15 days of treatment.
    1,033 patients were involved in the study, including 515 in the Barrettinib group and 518 in the placebo group.
    recovery time was 7 days in the Bariteni group and 8 days in the control group (recovery rate 1.16).
    15-day improvement in clinical status in the Barentinib group was 30% higher than in the placebo group (OR-1.3).
    for patients who received high-flow oxygen or noninvasive breath therapy at baseline, the average recovery time in the Barrettinib group was 10 days, while in the placebo group it was 18 days (recovery rate 1.51).
    28-day mortality rate was 5.1 per cent in the Bariteni group and 7.8 per cent in the control group (risk of death ratio 0.65).
    rates of serious adverse events (16 vs 21 per cent) and new infections (5.9 vs 11.2 per cent) were lower in the Bariteni group.
    study found that Barrettinib combined with Redsywe to shorten the recovery time of patients hospitalized with neocytic pneumonia and improve clinical conditions, especially in patients treated with high flow of oxygen or non-invasive breathing.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.